18 October 2021 - In this cross-sectional study among 37 348 patients who received 1 or more of 44 new oral targeted cancer drugs, the proportion of patients receiving drugs without documented overall survival benefit increased from 13% in 2011 to 59% in 2018, accounting for 52% of the $3.5 billion estimated cumulative spending on the new oral targeted cancer drugs by the end of 2018.

Results of this study suggest that the estimated use of new cancer drugs without documented clinical benefit has substantially increased over the past decade, with major cost implications.

Read JAMA Internal Medicine article